Zykadia may now be used as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors carry a specific enzyme identified through an FDA-approved test.
The drug first earned FDA approval in 2014 to treat metastatic non-small cell lung cancer patients who did not respond to the cancer drug crizotinib.
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Supply chain tip of the day: Schedule daily huddles with surgical teams
